版本:
中国

BRIEF-Gilead says presents data supporting efficacy and safety of Vemlidy in patients with chronic hepatitis B after 96 weeks

April 20 Gilead Sciences Inc

* Gilead sciences inc says presents data supporting efficacy and safety of vemlidy in patients with chronic hepatitis b after 96 weeks Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐